Sanofi-Aventis: A timeline of biopharma deals

Since Chris Viebacher was tapped as CEO of Sanofi-Aventis in September 2008, the company has inked more than $17 billion in deals. Now, with the latest deal rumored to be in the $20 billion range, we're looking back at Viebacher's deal-saturated reign.

TargeGen
Date:
 June 30, 2010
Estimated worth: $635M

Summary: Continuing its global deal-making spree, Sanofi-Aventis forged a deal to buy San Diego-based TargeGen for $75 million down and up to $560 million in milestones based on the success of its small molecule kinase inhibitors for leukemia, lymphoma and other blood diseases. Report

Metabolex
Date:
June 25, 2010
Estimated worth: $375M-plus

Summary: The developer secured an undisclosed upfront payment and up to $375 million from Sanofi-Aventis for rights to an experimental diabetes treatment. The two companies will collaborate on MBX-2982, a potent selective orally active GPR119 agonist which has completed three Phase I clinical studies and is currently a Phase II clinical study in patients with Type 2 diabetes. Report

Ascenta
Date: June 4, 2010
Estimated worth: $398M

Summary: Sanofi-Aventis paid for the rights to several of Ascenta Therapeutics' early-stage oral drug candidates. The French biotech gained access to MI-773 and MI-519-64, Ascenta's two most advanced drug candidates, which are expected to begin preclinical development later this year. Report

Nichi-iko
Date:
May 28, 2010
Estimated worth: $48M

Summary: Sanofi owns 51 percent of the joint venture, and as part of the deal bought a 4.66 percent stake in Nichi-iko. The J.V.'s first task was to take over marketing and distribution in Japan for Sanofi's sleep drug Amoban, which brought in sales of €43 million ($53 million) in Japan last year. Report

Nepentes
Date: May 19, 2010
Estimated worth: $130.4M (€105M)

Summary: Sanofi-Aventis unveiled a further push into emerging markets with plans to buy Polish consumer healthcare group Nepentes in a deal valuing it at around €105 million ($130.4 million). Report

Glenmark
Date: May 3, 2010
Estimated worth: $345M

Summary: India's Glenmark got $20 million upfront in the deal, along with royalties and a U.S. co-promotion agreement. Sanofi won marketing rights in North America, Europe and Japan for TRPV3 and GRC 15300, two drugs in a new class of pain remedies. Report

CureDM
Date: April 8, 2010
Estimated worth: $335M

Summary: The latest deal gave the drug giant the exclusive worldwide license of CureDm's Pancreate, a treatment for Type 1 and Type 2 diabetes. Sanofi has the rights to manufacture, develop and market Pancreate for diabetes in human and veterinary applications. Report

Merck
Date: March 9, 2010
Estimated worth: unknown

Summary: By combining the animal health business Merck acquired along with Schering-Plough--Intervet--with Sanofi's now-wholly-owned Merial, the companies created the biggest animal drugs-and-vaccines company in the world. Report

Sanofi-Aventis: A timeline of biopharma deals
Read more on

Suggested Articles

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

The action will see Kiadis switch its attention to earlier-stage natural killer cell therapies against solid tumors and hematological cancers.

The Weill Family Foundation is stumping up $106 million to create a so-called “Neurohub.”